SAR101099
/ Sanofi
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 28, 2020
Therapeutic potential of urotensin II receptor antagonist in chronic kidney disease and associated comorbidities.
(PubMed, J Pharmacol Exp Ther)
- "New potent, selective, orally long-acting cross species UT antagonist such as SAR101099 exerting reno- and cardio-protective effects could offer novel therapeutic opportunities. Its preclinical and clinical results suggest that UT antagonism remains an attractive target in CKD on top of current standard of care."
Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction • Nephrology • Renal Disease • Reperfusion Injury
1 to 1
Of
1
Go to page
1